First Drug of Its Kind Cuts Repeat Strokes by a Quarter
For someone who has just had a stroke, the most frightening question is often: will it happen again? On 9 November 2026, the US Food and Drug Administration (FDA) approved a new medicine that tackles exactly that fear — the first drug of a brand-new kind.
The medicine is called Sunharbo, and its chemical name is asundexian. It is made by Bayer and taken as a 50 mg tablet once a day, alongside standard antiplatelet medicine. It is for adults who have recently had a mild-to-moderate stroke caused by a clot that did not come from the heart, or a high-risk "mini-stroke" (a transient ischaemic attack, or TIA).
A new target in the blood
Blood clots are the body's repair kit: when a blood vessel is damaged, clotting proteins rush in and seal it. But when a clot forms in the wrong place — inside an artery feeding the brain — it can block the blood supply and cause a stroke. Existing blood thinners reduce clotting, but they also raise the risk of dangerous bleeding, because they interfere with the clotting the body still needs.
Sunharbo works differently. It blocks a single clotting protein called Factor XIa. Scientists have long suspected that Factor XIa matters more for harmful clots than for the everyday clotting that stops a cut from bleeding — so blocking it might prevent strokes without causing as much bleeding. Sunharbo is the first drug of this type ever approved in the United States.
What the trial showed
The approval rests on a large international trial called OCEANIC-STROKE, published in the New England Journal of Medicine in April 2026. It enrolled 12,327 adults at 702 centres in 37 countries, all within 72 hours of a stroke or high-risk mini-stroke. Half received Sunharbo plus antiplatelet medicine; half received a placebo plus antiplatelet medicine.
Over a median of 14.2 months of treatment, 6.2% of patients taking Sunharbo had another ischaemic stroke, compared with 8.4% of those on placebo — a 26% lower risk. Importantly, major bleeding was not significantly higher: 1.9% with Sunharbo versus 1.7% with placebo.
The limits matter too
The approval is deliberately narrow. Sunharbo is not approved to prevent strokes in people with atrial fibrillation — an irregular heartbeat that is a much larger market for blood thinners — because an earlier trial found asundexian less effective than an existing drug in that group. It is also not recommended for people with moderate or severe liver problems, and the FDA notes that bleeding risk rises in patients over 75.
Even so, this is a genuine milestone: the first new class of blood thinner in years, built on a simple idea from the science of clotting — block the protein that drives the harmful clot, and leave the rest of the system alone.
For students, the story is a neat example of how school science connects to real medicine: the clotting cascade they meet in GCSE biology, the idea of a clinical trial with a control group, and the careful arithmetic of risk — a 26% relative reduction that comes from comparing 6.2% with 8.4%.
If your child is curious about how the body works — from blood and clotting to the trials that test new medicines — a first lesson in biology can start with the questions this story raises. Book your first lesson
Sources:
- US Food and Drug Administration, "FDA approves first Factor XIa inhibitor to help prevent stroke in certain adults at high risk", 9 November 2026: https://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk
- Sharma, M., Dong, Q., Hirano, T., et al., "Asundexian for secondary stroke prevention", New England Journal of Medicine (2026)
London Tutors — post your tutoring request and we will match you with a verified tutor.